JP7280241B2 - 操作されたトランスフェリン受容体結合ポリペプチド - Google Patents

操作されたトランスフェリン受容体結合ポリペプチド Download PDF

Info

Publication number
JP7280241B2
JP7280241B2 JP2020506964A JP2020506964A JP7280241B2 JP 7280241 B2 JP7280241 B2 JP 7280241B2 JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020506964 A JP2020506964 A JP 2020506964A JP 7280241 B2 JP7280241 B2 JP 7280241B2
Authority
JP
Japan
Prior art keywords
seq
sequence
polypeptide
ala
polypeptide comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020506964A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530293A (ja
JP2020530293A5 (enExample
Inventor
シャオチェン チェン
マーク エス． デニス
ミハリス カリオリス
アダム ピー． シルバーマン
アンキタ スリヴァスタヴァ
ライアン ジェイ． ワッツ
ロバート シー． ウェルズ
ジョイ ユ ズチェロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/018371 external-priority patent/WO2018152326A1/en
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of JP2020530293A publication Critical patent/JP2020530293A/ja
Publication of JP2020530293A5 publication Critical patent/JP2020530293A5/ja
Application granted granted Critical
Publication of JP7280241B2 publication Critical patent/JP7280241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2020506964A 2017-08-10 2018-08-10 操作されたトランスフェリン受容体結合ポリペプチド Active JP7280241B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762543658P 2017-08-10 2017-08-10
US62/543,658 2017-08-10
US201762583314P 2017-11-08 2017-11-08
US62/583,314 2017-11-08
USPCT/US2018/018371 2018-02-15
PCT/US2018/018371 WO2018152326A1 (en) 2017-02-17 2018-02-15 Engineered transferrin receptor binding polypeptides
PCT/US2018/046199 WO2019032955A1 (en) 2017-08-10 2018-08-10 MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES

Publications (3)

Publication Number Publication Date
JP2020530293A JP2020530293A (ja) 2020-10-22
JP2020530293A5 JP2020530293A5 (enExample) 2021-09-16
JP7280241B2 true JP7280241B2 (ja) 2023-05-23

Family

ID=65272509

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020507090A Pending JP2020530465A (ja) 2017-08-10 2018-08-10 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2020506964A Active JP7280241B2 (ja) 2017-08-10 2018-08-10 操作されたトランスフェリン受容体結合ポリペプチド
JP2023107814A Pending JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2025090730A Pending JP2025120209A (ja) 2017-08-10 2025-05-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020507090A Pending JP2020530465A (ja) 2017-08-10 2018-08-10 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023107814A Pending JP2023123757A (ja) 2017-08-10 2023-06-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法
JP2025090730A Pending JP2025120209A (ja) 2017-08-10 2025-05-30 トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法

Country Status (19)

Country Link
US (4) US20200369746A1 (enExample)
EP (2) EP3665192B1 (enExample)
JP (4) JP2020530465A (enExample)
CN (2) CN111094336A (enExample)
CA (2) CA3072051A1 (enExample)
DK (1) DK3665192T5 (enExample)
ES (1) ES2956062T3 (enExample)
FI (1) FI3665192T3 (enExample)
HR (1) HRP20231118T1 (enExample)
HU (1) HUE063021T2 (enExample)
LT (1) LT3665192T (enExample)
MD (1) MD3665192T2 (enExample)
PL (1) PL3665192T3 (enExample)
PT (1) PT3665192T (enExample)
RS (1) RS64584B1 (enExample)
SI (1) SI3665192T1 (enExample)
SM (1) SMT202300347T1 (enExample)
TW (1) TWI821197B (enExample)
WO (2) WO2019032955A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
BR112021002953A2 (pt) * 2018-08-22 2021-05-11 Denali Therapeutics Inc. polipeptídeos anti-her2 e métodos de uso dos mesmos
WO2020172457A1 (en) 2019-02-20 2020-08-27 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP2023507846A (ja) 2019-12-23 2023-02-27 デナリ セラピューティクス インコーポレイテッド プログラニュリン変異体
AU2021208482B2 (en) * 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
EP4181950A4 (en) * 2020-02-19 2024-07-17 Denali Therapeutics Inc. Engineered anti-her2 bispecific proteins
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
CA3230796A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
EP4458848A4 (en) * 2021-12-31 2025-12-03 Imnewrun Inc BLOOD-BRAIN BARRIER PERMEABLE FUSION PROTEIN AND ITS USES
IL318636A (en) 2022-07-29 2025-03-01 Regeneron Pharma Viral particles retargeted to transferrin receptor 1
EP4561636A1 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
EP4562041A2 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
WO2024026488A2 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
WO2024130116A2 (en) * 2022-12-16 2024-06-20 Denali Therapeutics Inc. Methods and compositions related to engineered transferrin receptor‑binding molecules
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
AR133385A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Inserción anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2017055540A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513016A (ja) * 1999-08-30 2003-04-08 ニューヨーク・ユニバーシティ レセプタータンパク質チロシンキナーゼのドメイン、およびそのリガンドの結晶構造
CN101516907B (zh) * 2006-08-01 2015-08-26 皮里斯股份公司 泪液脂质运载蛋白的突变蛋白及其获得方法
SI2646470T1 (sl) * 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
RS58928B1 (sr) * 2012-08-29 2019-08-30 Hoffmann La Roche Transporter za krvno-moždanu barijeru
JP6557664B2 (ja) * 2014-01-06 2019-08-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価の血液脳関門シャトルモジュール
SG10201912019WA (en) * 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
WO2016077840A2 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS
CN107250158B (zh) * 2014-11-19 2022-03-25 基因泰克公司 抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
MY193078A (en) * 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526878A (ja) 2013-05-20 2016-09-08 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2016081643A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
WO2017055540A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOBNER E. et al. ，ENGINEERED IGG1-FC - ONE FRAGMENT TO BIND THEM ALL，IMMUNOLOGICAL REVIEWS，2016年03月，Vol.270, No.1，pp.113 - 131，http://dx.doi.org/10.1111/imr.12385

Also Published As

Publication number Publication date
HRP20231118T1 (hr) 2023-12-22
RS64584B1 (sr) 2023-10-31
EP3665192A1 (en) 2020-06-17
SI3665192T1 (sl) 2023-11-30
TW201920278A (zh) 2019-06-01
PT3665192T (pt) 2023-09-25
MD3665192T2 (ro) 2023-12-31
LT3665192T (lt) 2023-10-25
JP2025120209A (ja) 2025-08-15
US20200369746A1 (en) 2020-11-26
DK3665192T3 (da) 2023-10-09
JP2020530293A (ja) 2020-10-22
CA3072051A1 (en) 2019-02-14
EP3665192B1 (en) 2023-07-12
DK3665192T5 (da) 2024-08-26
EP3665194A1 (en) 2020-06-17
HUE063021T2 (hu) 2023-12-28
FI3665192T3 (fi) 2023-09-28
CN111148757B (zh) 2024-06-21
US20200289627A1 (en) 2020-09-17
CN111094336A (zh) 2020-05-01
EP3665194A4 (en) 2021-07-07
WO2019032955A1 (en) 2019-02-14
ES2956062T3 (es) 2023-12-12
PL3665192T3 (pl) 2023-11-27
US20230381286A1 (en) 2023-11-30
CA3072035A1 (en) 2019-02-14
CN111148757A (zh) 2020-05-12
JP2020530465A (ja) 2020-10-22
TWI821197B (zh) 2023-11-11
JP2023123757A (ja) 2023-09-05
US20240024432A1 (en) 2024-01-25
WO2019033046A1 (en) 2019-02-14
SMT202300347T1 (it) 2023-11-13

Similar Documents

Publication Publication Date Title
JP7280241B2 (ja) 操作されたトランスフェリン受容体結合ポリペプチド
US12162948B2 (en) Methods of engineering transferrin receptor binding polypeptides
US11732023B2 (en) Engineered polypeptides
JP2023058568A (ja) 操作されたポリペプチド
HK40031478A (en) Engineered transferrin receptor binding polypeptides
HK40031478B (en) Engineered transferrin receptor binding polypeptides
HK40018508A (en) Engineered transferrin receptor binding polypeptides
HK40019963B (en) Engineered transferrin receptor binding polypeptides
HK40019963A (en) Engineered transferrin receptor binding polypeptides
BR122024019261A2 (pt) Região fc, polipeptídeo e seu uso, polinucleotídeo, método para aumentar a ligação de uma região fc compreendendo um domínio ch3 a um tfr1 humano, métodos para manipular um domínio ch3 de uma região fc para se ligar a um tfr1 humano e para manipular um domínio ch3 ou ch2 para se ligar especificamente a um receptor de transferrina, composição, método para produzir um polipeptídeo compreendendo um domínio ch3 modificado ou um domínio ch2 modificado, método para transcitose de uma composição
EA049739B1 (ru) Сконструированные полипептиды, связывающие трансферриновый рецептор

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230511

R150 Certificate of patent or registration of utility model

Ref document number: 7280241

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150